Risk Analysis for Reverse Mortgages with Different Payout Designs
Asia-Pacific Journal of Risk and Insurance · 2015
DOI: 10.1515/apjri-2014-0012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Risk and Insurance, 2015. Verfasst von Daniel Cho und 2 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
We analyze the risk and profitability of reverse mortgages with lump-sum or income stream payments from the lender’s perspective. Reverse mortgage cash flows and loan balances are modeled in a multi-period stochastic framework that allows for house price risk, interest rate risk and risk of delayed loan termination. A vector autoregressive (VAR) model is used to simulate economic scenarios and to derive stochastic discount factors for pricing the no negative equity guarantee embedded in reverse mortgage contracts. Our results show that lump-sum reverse mortgages are more profitable and require less risk-based capital than income stream reverse mortgages, which explains why this product design dominates in most markets. The loan-to-value ratio, the borrower’s age, mortality improvements and the lender’s financing structure are shown to be important drivers of the profitability and riskiness of reverse mortgages, but changes in these parameters do not change the main conclusions.
Zitieren
APA
Cho, D., Hanewald, K., & Sherris, M. (2015). Risk Analysis for Reverse Mortgages with Different Payout Designs. Asia-Pacific Journal of Risk and Insurance. https://doi.org/10.1515/apjri-2014-0012
Vancouver
Cho D, Hanewald K, Sherris M. Risk Analysis for Reverse Mortgages with Different Payout Designs. Asia-Pacific Journal of Risk and Insurance. 2015. doi:10.1515/apjri-2014-0012
BibTeX
@article{Cho2015,
author = {Cho, Daniel and Hanewald, Katja and Sherris, Michael},
title = {Risk Analysis for Reverse Mortgages with Different Payout Designs},
journal = {Asia-Pacific Journal of Risk and Insurance},
year = {2015},
doi = {10.1515/apjri-2014-0012}
}
EUVIMED